CINF
37
6
NOV
52
3
AVGO
25
-2
A
47
6
WBA
48
-2
TJX
42
-9
DFS
56
-4
BXP
47
3
RF
53
-3
JCI
42
-5
KHC
22
-3
SLG
62
3
HRB
54
2
HIG
52
2
MDT
59
-3
BRK.B
33
-3
ROK
38
-14
CF
53
3
OMC
59
4
PYPL
41
2
CINF
37
6
NOV
52
3
AVGO
25
-2
A
47
6
WBA
48
-2
TJX
42
-9
DFS
56
-4
BXP
47
3
RF
53
-3
JCI
42
-5
KHC
22
-3
SLG
62
3
HRB
54
2
HIG
52
2
MDT
59
-3
BRK.B
33
-3
ROK
38
-14
CF
53
3
OMC
59
4
PYPL
41
2
Financhill
Back

Cidara Therapeutics 10K Form

Buy
62

CDTX
Cidara Therapeutics

Last Price:
13.12
Seasonality Move:
7.06%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CDTX News And Ratings

See the #1 stock for the next 7 days that we like better than CDTX

CDTX Financial Statistics

Sales & Book Value

Annual Sales: $63.91M
Cash Flow: $-103.78M
Price / Cash Flow: 0
Annual Sales: $28.66
Price / Book: 0.7

Profitability

EPS (TTM): -25.27000
Net Income (TTM): $-115.32M
Gross Margin: $62.38M
Return on Equity: -449.07%
Return on Assets: -135.81%

Cidara Therapeutics Earnings Forecast

Key Cidara Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for CDTX is 97.62%.
  • The Selling, General & Administrative Expenses for CDTX have been equal to 28.69% of Gross Profit Margin.
  • The Research & Development expenses have been 107.24% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 11 years have been positive in 6 years.

Cidara Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CDTX
CUSIP: 171757
Website: cidara.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.25
Quick Ratio: 4.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 4.45

CDTX Technical Analysis vs Fundamental Analysis

Buy
62
Cidara Therapeutics (CDTX) is a Buy

Is Cidara Therapeutics a Buy or a Sell?